59 min
New RSV Monoclonal Antibody and Vaccine Conversation PHM from Pittsburgh
-
- Medicine
Title: New RSV Monoclonal Antibody and Vaccine Conversation
Target Audience
This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards.
Objectives:
Upon completion of this activity, participants should be able to:
Review how monoclonal antibodies work in fightin disease. Review Nirsevimab and the ACIP and AAP reccomendations for its use. Discuss how monoclonal antibodies are different from vaccines and discuss the new RSV vaccines being released. Faculty:
Planning Committee:
Maha Kaissi, MD, MHPE — Assistant Professor of Pediatrics, Division of Pediatric Hospital Medicine, UPMC Children's Hospital of Pittsburgh
Course Directors:
Tony R. Tarchichi MD — Assistant Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine
Dr. Tarchichi has disclosed he was a member of the Advisory Board for meningococcal vaccine in immunocompromised patient for Sanofi Corp
John Williams, MD — Professor in the Dept. of Pediatrics at the University of Pittsburgh, Division Director for Pediatric Infectious Disease Division at University of Pittsburgh Medical Center (UPMC).
Conflict of Interest Disclosure:
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation Statement:
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Disclaimer Statement:
The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Released 8/29/2023, Expires 8/29/2026
The direct link to the course is provided below:
COMING SOON!!
Title: New RSV Monoclonal Antibody and Vaccine Conversation
Target Audience
This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards.
Objectives:
Upon completion of this activity, participants should be able to:
Review how monoclonal antibodies work in fightin disease. Review Nirsevimab and the ACIP and AAP reccomendations for its use. Discuss how monoclonal antibodies are different from vaccines and discuss the new RSV vaccines being released. Faculty:
Planning Committee:
Maha Kaissi, MD, MHPE — Assistant Professor of Pediatrics, Division of Pediatric Hospital Medicine, UPMC Children's Hospital of Pittsburgh
Course Directors:
Tony R. Tarchichi MD — Assistant Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine
Dr. Tarchichi has disclosed he was a member of the Advisory Board for meningococcal vaccine in immunocompromised patient for Sanofi Corp
John Williams, MD — Professor in the Dept. of Pediatrics at the University of Pittsburgh, Division Director for Pediatric Infectious Disease Division at University of Pittsburgh Medical Center (UPMC).
Conflict of Interest Disclosure:
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation Statement:
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Disclaimer Statement:
The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Released 8/29/2023, Expires 8/29/2026
The direct link to the course is provided below:
COMING SOON!!
59 min